Could a simple sugar ease Crohn's? new trial aims to find out
NCT ID NCT07225998
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether an oral supplement called N-acetylglucosamine (GlcNAc) can safely help control Crohn's disease in the ileum or ileocolon. Forty adults with stable Crohn's will receive either GlcNAc or a placebo for 6 weeks, then switch after a washout period. The study focuses on safety and symptom changes, and includes people with and without a specific genetic variant linked to the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-acetylglucosamine (GlcNAc)
What this could lead to
If it works, this could point toward a new treatment option for Crohn's disease, especially for patients with a specific genetic mutation.
What could go wrong
This is a small, early-phase proof-of-concept study. It may not show clear benefit, and results may not apply to all Crohn's patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••